Who official: China’s international contribution to vaccine as a public product

Two new inactivated vaccines against coronavirus in my country were approved for clinical trials in Phase I and Phase II mergers in April. The picture shows the staff testing the purity of the new inactivated vaccine sample.

Xinhua News Agency reporter Zhang Yuwei photo

Faced with the challenge of the New Coronary Pneumonia epidemic, the World Health Organization launched a number of international cooperation initiatives to promote the development, production and equitable distribution of the New Crown Vaccine, and progress has been made in vaccine development in many countries. China has always adhered to the concept of a community of human destiny. It shared the new coronavirus genome information with all countries in the world, established a platform for sharing data and scientific research results, and actively carried out international cooperation in drug and vaccine research and development. The international community’s firm determination to work together against the epidemic.

“The new crown vaccine is a simple, safe and effective way to fight the epidemic”

Since the outbreak of the New Coronary Pneumonia, scientific research institutions and enterprises in many countries have invested in the research and development of New Coronary Vaccine and promoted relevant international cooperation. According to WHO statistics, as of June 2, there are more than 130 candidate vaccines being developed worldwide. According to data from the US Bill and Melinda Gates Foundation, there are currently four vaccines in clinical phase II trials in the world, three vaccines are undergoing clinical phase I and II trials, and two vaccines are undergoing phase I trials.

Germany, France, Italy and the Netherlands started to develop vaccines against the new coronavirus. The four countries stated that they will “discuss the most promising options together” and are negotiating with pharmaceutical companies to develop vaccines in Europe to provide sufficient vaccines for EU member states and low-income countries in Africa.

The German government has invested nearly 1 billion euros to support the development of vaccines in the country. In April this year, the German Ministry of Health and the vaccine approval agency Paul Ellich Institute announced the approval of Germany’s first clinical trial of a new crown vaccine. It is reported that this vaccine was developed by a biotech company based in Germany. In order to speed up the development of vaccines, under the premise of risk permitting, the Paul Ellich Institute appropriately reduced the approval process, completed the vaccine clinical trial authorization in only 4 days, and allowed the simultaneous development of vaccine animal experiments and pre-clinical human trials. The institute said that Germany will also start more clinical trials of new crown vaccines.

Russian Deputy Prime Minister Golikova said recently that the three new crown vaccines developed by Russian scientific research institutions are expected to be registered and put into production in the Russian national institutions this year: The Russian National Research Center for Epidemiology and Microbiology is working with the Russian Ministry of Defense A subordinate institute carried out clinical trials of the new crown vaccine. According to the plan, this clinical trial will end in August this year; the Russian “Vector” National Science Center will carry out the clinical trial of the new crown vaccine from June to September; It is planned to take place from September to December this year.

A new crown vaccine developed by the Imperial College of the United Kingdom has entered the animal experiment stage in early February and is scheduled to enter clinical trials in June. The Oxford University New Crown Vaccine R&D project has entered clinical trials in April. The British government plans to provide a total of 84 million pounds (about 100 million US dollars) for these two R&D projects to accelerate the development of vaccines.

On June 12, WHO Director-General Tan Desai said at a regular press conference: “The new crown vaccine is a simple, safe and effective way to fight the epidemic. The vaccine saves millions of lives every year. Vaccine research and development, production and equitable distribution are very important. The international consensus based on the political commitment of leaders of all countries is very important. The leaders of many countries have promised to use the new crown vaccine as an international public product. This is the right direction and requires more countries to join and support This commitment.”

“Work together to ensure that everyone in every place can get the vaccine”

Promoting the R&D, production and rational distribution of the new crown vaccine requires more international cooperation. In April of this year, WHO launched the International Cooperation Initiative on “Obtaining Accelerators for Fighting New Coronary Pneumonia” to accelerate the development, production and equitable distribution of new crown vaccines, diagnostic and therapeutic tools. Recently, WHO officially launched the “acquisition pool” initiative of the new coronary pneumonia epidemic response technology, which will accelerate the research and development of vaccines, drugs and other health technologies through open scientific research.

“Traditional market models cannot meet the scale needed for new crown vaccines and drugs to cover the world. Close solidarity within and among countries, as well as between the private sector, is essential.” Tan Desai said that since January this year, WHO The organization has been working with thousands of researchers around the world to accelerate vaccine development and track progress. “Only unity can contain the epidemic. All countries, health partners, manufacturers and the private sector must work together to ensure that science and research results benefit everyone.”

UN Secretary General Guterres said that there is no effective new crown vaccine, but the vaccine is not enough. “We need the world to work together to ensure that everyone in every place can get the vaccine.”

“The pandemic in the global pandemic transcends national borders. It is impossible for all countries to close themselves, and collective cooperation can solve this problem.” Richard Hatchett, CEO of the Epidemic Prevention Innovation Alliance, said that international cooperation can accelerate Vaccine research and development, and the production and distribution of vaccines after research and development, also require strong international cooperation to provide guarantees. “We need to establish a fair global distribution system that can operate effectively after vaccine development. This system requires funding, management, and global support and collaboration.”

“From basic research, clinical trials, to preparation, production and distribution, the new crown vaccine requires more international cooperation to accelerate the achievement of its goals. Therefore, cross-border, cross-company cooperation, and collaborative cooperation between scientific research institutions are critical.” Robert Scully, director of the Department of Infectious Diseases at the University of California, San Diego, said that extensive international cooperation from governments, international organizations, non-profit organizations, and enterprises can promote the rapid availability of vaccines and help the global availability of vaccines. Is fair and accessible.

“Using the new crown vaccine as a global public product is a real contribution to the international community”

President Xi Jinping announced at the opening ceremony of the video conference of the 73rd World Health Assembly that after the completion of the development and use of the new Chinese crown vaccine, it will be used as a global public product to make the vaccine accessible and affordable in developing countries. Chinese contribution.

China conducts vaccine research and development in accordance with five technical routes including inactivated vaccines, recombinant protein vaccines, attenuated influenza virus vector vaccines, adenovirus vector vaccines, and nucleic acid vaccines. At present, four inactivated vaccines and one adenovirus vector vaccine have been approved for clinical trials. The overall R&D progress is the same as that of foreign countries, and the progress of some technical routes is in the international lead.

David Nabarro, WHO’s special envoy for the prevention and control of the new coronary pneumonia epidemic, believes that the successful development of the vaccine will be an important progress in combating the epidemic, and “giving everyone access to affordable vaccines is even more remarkable. China regards the new crown vaccine as a global Public goods are a real contribution to the international community.”

“The five vaccine R&D technology routes that China is advancing simultaneously are all open to the outside world, and they cooperate with other countries’ enterprises or research institutions to contribute to the promotion of international cooperation in the research and development of the new crown vaccine.” Zhu Tao, co-founder and chief scientist of China Kangxinuo Biology .

Jiang Shibo, director of the Institute of Pathogenic Microbiology at Fudan University in Shanghai, said that China has the world’s advanced vaccine research and development platform and production base and is positive about international cooperation in the development of new crown vaccines. Chinese companies have actively participated in the construction of a global vaccine industry chain. For example, Shanghai Fosun Pharma Group and German Biotech have reached a cooperation intention to jointly promote the company’s clinical trials and subsequent commercialization of the mRNA new crown vaccine in China.

Published papers in internationally renowned academic journals such as “The Lancet”, “Science”, “Nature”, “New England Medical Journal”, and released research results such as drug development progress and vaccine experiment results in a timely manner; with relevant countries, WHO and epidemics Preventive Innovation Alliance, Global Vaccine Immunization Alliance, etc. carry out scientific research cooperation to accelerate the development of vaccine research and drug clinical trials… “China has always practiced the concept of the community of human destiny with practical actions, showing a positive attitude towards vaccine development and international cooperation in anti-epidemic, An important contribution to global public health.” Ben Gon Sihavon, the chairman of the 72nd World Health Assembly and the Laotian Minister of Health, believes that China supports WHO to play a central role in coordinating vaccine research and development and promote multi-center clinical vaccines. The results of trials and R&D have been put on the market as soon as possible, providing safe, effective, and high-quality global public products to the world, which exemplifies the role of major countries promoting international cooperation in the fight against epidemics.

“From providing international assistance to support countries affected by the epidemic, to promising that China’s new crown vaccine will be developed and put into use as a global public product, China will actively respond to WHO’s global cooperation initiatives with practical actions to promote vaccines, etc. The fair distribution of related products makes unremitting efforts to maintain global health security.” Kulikova, the first vice-chairman of the Russia-China Friendship Association, believes that in the face of this war between humanity and viruses, China is active and brave, with an open attitude Share the anti-epidemic experience and achievements with the world, and work together to meet this human challenge.

Leave a Reply

Your email address will not be published. Required fields are marked *